Desentum

About:

Desentum is a biotechnology company in Finland developing an allergy vaccine that harnesses the immune system.

Website: http://www.desentum.fi/en/

Twitter/X: desentumAIT

Top Investors: European Innovation Council, Springvest, Cascara Ventures, VTT Ventures, Sto-Rahoitus

Description:

Desentum is a research-oriented biopharmaceutical company specialized in developing novel types of allergy vaccines that are based on switching the immune system's response to allergens from hypersensitivity to tolerance. They have a unique approach for designing allergy vaccines. By studying the molecular mechanism of the hypersensitivity reaction, they have made discoveries that allow for improved design of vaccines against common types of allergies. Their goal is to provide long-term relief for patients suffering from allergic symptoms, as well as reduce the social and economic burden allergies cause to both individuals and society.